Baxter Gets Complete Response Letter On HyQ Therapy Fox Business The FDA's letter delays any potential approval of HyQ, a treatment that aims to allow physicians to tailor antibody drug therapy to the lifestyle and medical needs of patients with immune – system disorders. Halozyme shares plunged 50% to $4.25 after … Halozyme shares plunge on FDA safety questions Bioscience Technology all 70 news articles
Click here for more interesting articles
Tags: Immune support